Sort
48,018 grants matching “immunotherapy”
Targeting metabolic stress to induce pancreatic tumor cell death
$384,227Costas Andreas Lyssiotis · University Of Michigan At Ann Arbor · R01 · FY2022 · CA
Interactions of ES Cells with 3D Biomaterials
$384,199Krishnendu Roy · University Of Texas At Austin · R01 · FY2009 · EB
Synergy of Radiation and Immunotherapy: New Approaches
$384,156Yang-Xin Fu · Ut Southwestern Medical Center · R01 · FY2016 · CA
Role of immune cell OGR1 in prostate cancer development and the mechanisms involv
$384,136Yan Xu · Indiana University Indianapolis · R01 · FY2013 · CA
RNase H2 is a novel therapeutic target in triple negative breast cancer
$384,115Shiaw-Yih Lin · University Of Tx Md Anderson Can Ctr · R01 · FY2025 · CA
RNase H2 is a novel therapeutic target in triple negative breast cancer
$384,115Shiaw-Yih Lin · University Of Tx Md Anderson Can Ctr · R01 · FY2021 · CA
MAIT cells as a therapeutic approach for gastrointestinal cancers
$384,092Daniel Ted Leung · University Of Utah · R21 · FY2024 · CA
High dose radiation therapy to direct immune responses to pancreatic cancer
$384,038Michael James Gough · Providence Portland Medical Center · R01 · FY2022 · CA
High dose radiation therapy to direct immune responses to pancreatic cancer
$384,038Michael James Gough · Providence Portland Medical Center · R01 · FY2023 · CA
Silencing of HIV-1 proviruses by epigenetically targeting transcriptional elongation
$384,023Qin Feng · University Of Houston · R61 · FY2019 · AI
Molecular Genetic Analysis of Mycobacterium tuberculosis
$383,996William Robert Jacobs · Albert Einstein College Of Medicine, Inc · R01 · FY2018 · AI
Methamphetamine and HIV: Defective immunity with CD8 T cell dysfunction
$383,992Howard S. Fox · University Of Nebraska Medical Center · R01 · FY2011 · DA
Phase I Clinical Trials of Novel Agents
$383,985Sloan-Kettering Institute For Cancer Res · U01 · FY2003 · CA
GENE EXPRESSION PROFILE OF PROGRESSION &RESPONSE IN CML
$383,961Fred Hutchinson Cancer Research Center · U01 · FY2001 · CA
Determining susceptibility loci in triple negative breast cancer using a novel pre-clinical model
$383,960Liza Makowski Hayes · University Of Tennessee Health Sci Ctr · R01 · FY2024 · CA
Structural Requirements of glycolipid/CD1d Recognition by NKT Cells
$383,958Laurent Gapin · University Of Colorado Denver · R56 · FY2009 · AI
Modulating pathogenic T cells in Type 1 diabetes
$383,940Kevan C Herold · Yale University · R01 · FY2023 · DK
SMART NANPs: new molecular platform for communication with human immune system and modulation of therapeutic responses
$383,939Kirill A Afonin · University Of North Carolina Charlotte · R35 · FY2025 · GM
Validating Urine Derived Cancer Cells (UDCC) -- Non-Invasive and Living Liquid Biopsies -- in Bladder Cancer Clinics
$383,927Xuefeng Liu · Ohio State University · R33 · FY2023 · CA
Biased chemokine receptor signaling in cancer progression
$383,920Michael B Dwinell · Medical College Of Wisconsin · R01 · FY2022 · CA
Engineering Nanomaterials to Prime Immunity
$383,908James J. Moon · University Of Michigan At Ann Arbor · R01 · FY2019 · CA
IMMUNOTHERAPY PROTECTION &VACCINES FOR HEPATITIS C
$383,896Rockefeller University · R01 · FY2001 · CA
Multiplexed nanoparticle delivery to increase CRISPR/Cas gene editing for enhanced cancer therapy
$383,887Daniel John Siegwart · Ut Southwestern Medical Center · R01 · FY2023 · CA
Promotion of tumor invasion and pseudosenescence by the aging microenvironment
$383,875Ashani T Weeraratna · Wistar Institute · R01 · FY2014 · CA
Promotion of tumor invasion and pseudosenescence by the aging microenvironment
$383,875Ashani T Weeraratna · Wistar Institute · R01 · FY2015 · CA